Compare AMSS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSS | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 35.2M |
| IPO Year | 2026 | 2008 |
| Metric | AMSS | NNVC |
|---|---|---|
| Price | $0.72 | $1.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.7K | ★ 424.9K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.85 |
| 52 Week High | $2.44 | $2.23 |
| Indicator | AMSS | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 73.38 |
| Support Level | $0.60 | $1.15 |
| Resistance Level | $1.35 | $1.67 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.92 | 95.40 |
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.